Beyond Air® Announces Transition of Chief Financial Officer

GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity.

GlobeNewsWire • Nov 26, 2025

Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript

Beyond Air, Inc. ( XAIR ) Q2 2026 Earnings Call November 10, 2025 4:30 PM EST Company Participants Steven Lisi - CEO & Chairman of the Board Douglas Larson - Chief Financial Officer Conference Call Participants Garth Russell - Lifesci Advisors, LLC Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd., Research Division Sam Eiber - BTIG, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Beyond Air financial results call for the fiscal quarter ended September 30, 2025.

Seeking Alpha • Nov 10, 2025

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10 th GARDEN CITY, N.Y.

GlobeNewsWire • Nov 10, 2025

Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Douglas Larson, Chief Financial Officer of Beyond Air, will participate in the ROTH 4th Annual Healthcare Opportunities Conference, which is being held on Thursday, October 9, 2025, in New York, NY.

GlobeNewsWire • Sep 22, 2025

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding common warrants (the “Existing Warrants”) to purchase up to an aggregate of 1,439,126 shares of the Company's common stock at a reduced exercise price of $2.21 (the closing price of the Company's shares of common stock on September 5, 2025). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.25 million, prior to deducting placement agent fees and estimated offering expenses.

GlobeNewsWire • Sep 8, 2025

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.

GlobeNewsWire • Sep 3, 2025

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people

GlobeNewsWire • Aug 20, 2025

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2026 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Douglas Quinton Larson - Chief Financial Officer Steven Adam Lisi - CEO & Chairman of the Board Conference Call Participants I-Eh Jen - Laidlaw & Company (UK) Ltd., Research Division Jason Hart Wittes - ROTH Capital Partners, LLC, Research Division Jason M.

Seeking Alpha • Aug 12, 2025

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $5.4 per share a year ago.

Zacks Investment Research • Aug 12, 2025

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

GlobeNewsWire • Jul 25, 2025